ArticleCurrent rheumatology reports2008
Remission in psoriatic arthritis.
Article in Current rheumatology reports, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 16 citations in OpenAlex.
- Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs.Clinical rheumatology · 2010Trial
- A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor.Rheumatology and therapy · 2017Article
- [Psoriatric arthritis - a permanent challenge for rheumatologists and patients: part 2: imaging diagnostics, classification and therapy].Zeitschrift fur Rheumatologie · 2011Article
- Is remission a more realistic goal in psoriatic arthritis?Therapeutic advances in musculoskeletal disease · 2011Article
- Remission in psoriatic arthritis: is it possible and how can it be predicted?Arthritis research & therapy · 2010Article
- Remission makes its way to rheumatology.Arthritis research & therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis that can lead to joint deformity and disability. PsA has a low likelihood of clinical remission and cure. For a long time, therapeutic options for PsA patients have been unsatisfactory, but the introduction of anti-tumor necrosis factor agents have markedly improved articular and cutaneous signs and symptoms. The efficacy of tumor necrosis factor blockers also raised the bar for treatment goals in PsA. Remission may now be an attainable outcome in the treatment paradigm. At this time, specific tools to define PsA remission are not available. New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.